Henderson Morley announces KHV vaccine results

237f7902-787f-46f9-8202-e3a0d524c66f

Editor's Picks


Biotechnology company Henderson Morley has announced successful results from its vaccine against the fish disease Koi Herpes Virus (KHV).

Henderson Morley claims that field studies, undertaken by a sub-contracted research facility, have produced 'positive results' with 93% and 96% of vaccinated fish remaining healthy and surviving exposure to KHV.

It is now undertaking further development of two successful vaccine candidates with Schering Plough Animal Health.

Chairman Andrew Knight said: "We are extremely pleased with the results of this study which demonstrate a high level of efficacy for our vaccine technology and reinforces our decision to transform Henderson Morley into a pure play vaccine company by 2011."

News of the results of the study sent Henderson Morley's share rocketing by 28.5%.

KHV, which is now officially known as Cyprinid Herpes Virus 3 (CyHV-3) is now a notifiable disease in the UK. It affects Koi and Common carp and has led to mass mortalities in fish stocks in the wild and in captivity around the world.